722-P: Inhaled Insulin Improves Daytime Time-in-Range in People with Type 2 Diabetes
| Autor: | Lee A. Bromberger, Philip Levin, Lane Desborough |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Meal
medicine.medical_specialty endocrine system diseases Combination therapy business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment nutritional and metabolic diseases Type 2 diabetes Hypoglycemia medicine.disease Postprandial Diabetes mellitus Internal medicine Internal Medicine Medicine Dosing business |
| Zdroj: | Diabetes. 70 |
| ISSN: | 1939-327X 0012-1797 |
| DOI: | 10.2337/db21-722-p |
| Popis: | Background and Aims: Technosphere Insulin (TI), an inhaled insulin with ultra-rapid onset and short duration of action that more closely mimics physiologic insulin, may improve patient outcomes. To address the challenge of prandial control of glucose in type 2 diabetes (T2D), this study aimed to determine real-world dosing requirements, safety, and efficacy of TI in patients with uncontrolled T2D. Methods: Twenty patients with T2D inadequately controlled with oral/injectable combination therapy excluding prandial insulin in a real-world setting with TI added to current therapy. Dosing started at 4 units of TI per meal and increased up to 12 units per meal over a week and then titrated weekly based on postprandial SMBG. HbA1c and CGM profiles were collected at baseline and 12 weeks. Results: Nineteen patients completed the study with baseline and treatment CGM data. For the daytime period (6:00-24:00), there were significant decreases in mean CGM values, significant decreases in time spent in hyperglycemia, and significant increases in time-in-range without a significant increase in hypoglycemia. Conclusions: Addition of TI in patients with uncontrolled type 2 diabetes results in a significant increase in daytime CGM time-in-range (from 38.7% to 62.1%, a mean of over 4 hours of increased daytime time-in-range per day) without an increase in hypoglycemia and a significant reduction in both Level 1 and Level 2 hyperglycemia. Disclosure L. Desborough: Consultant; Self; Diabetes & Glandular Disease Clinic, Diasome Pharmaceuticals, Inc., Luna Health, MODEL Clinical Research, Roche Diabetes Care, Securecell AG, Tandem Diabetes Care, Tidepool. P. Levin: Research Support; Self; MannKind Corporation, Mylan N. V., Speaker’s Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Sanofi. L. A. Bromberger: None. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|